Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 1;13(1):69–76. doi: 10.3892/ol.2016.5456

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Aoyama et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Therapeutic response following KORTUC II treatment as evaluated by PET-CT examination of patient number 4 (58-year-old female with stage IV primary breast cancer). (A) PET-CT prior to induction chemotherapy with epirubicin and cyclophosphamide. Numerous lymph node and skin metastases are depicted. (B) PET-CT prior to KORTUC II treatment. With induction chemotherapy, FDG accumulation in the right breast and right axilla improved and the skin metastases disappeared. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose. (C) Four months following KORTUC II treatment. FDG accumulation in the left breast and in the chest disappeared. (D) PET-CT seven months following KORTUC II treatment. FDG accumulation had not recurred on the PET-CT scan conducted (E) 16 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose. PET-CT scans conducted (F) 21 months, (G) 26 months and (H) 32 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography. PET-CT scans conducted (I) 38 months, (J) 49 months and (K) 64 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography. PET-CT scan conducted (L) 76 months following KORTUC II treatment. FDG accumulation and recurrence of metastasis were not observed during follow-up. Prior to treatment, the size of the right breast tumor was 28 mm and the SUVmax of FDG accumulation was 8.6. The target lesion and the FDG accumulation had disappeared four months following KORTUC II treatment, as determined by a PET-CT scan. The therapeutic effect was determined to be a complete response in patient number 4. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose; SUVmax, max value of the standardized uptake value.

Figure 3. — Therapeutic response following KORTUC II treatment as evaluated by PET-CT examination of patient number 4 (58-year-old female with stage IV primary breast cancer). (A) PET-CT prior to induction chemotherapy with epirubicin and cyclophosphamide. Numerous lymph node and skin metastases are depicted. (B) PET-CT prior to KORTUC II treatment. With induction chemotherapy, FDG accumulation in the right breast and right axilla improved and the skin metastases disappeared. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose. (C) Four months following KORTUC II treatment. FDG accumulation in the left breast and in the chest disappeared. (D) PET-CT seven months following KORTUC II treatment. FDG accumulation had not recurred on the PET-CT scan conducted (E) 16 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose. PET-CT scans conducted (F) 21 months, (G) 26 months and (H) 32 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography. PET-CT scans conducted (I) 38 months, (J) 49 months and (K) 64 months following KORTUC II treatment. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography. PET-CT scan conducted (L) 76 months following KORTUC II treatment. FDG accumulation and recurrence of metastasis were not observed during follow-up. Prior to treatment, the size of the right breast tumor was 28 mm and the SUVmax of FDG accumulation was 8.6. The target lesion and the FDG accumulation had disappeared four months following KORTUC II treatment, as determined by a PET-CT scan. The therapeutic effect was determined to be a complete response in patient number 4. KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; PET-CT, positron emission tomography-computed tomography; FDG, fluorodeoxyglucose; SUVmax, max value of the standardized uptake value.